阿托伐他汀对急性冠脉综合征患者C－反应蛋白和内脂素水平的影响

Effect of Atorvastatin on the levels of C-reactive protein and visfatin in patients with acute coronary syndrome

【目的】探讨阿托伐他汀对急性冠脉综合征患者C－反应蛋白和内脂素水平的影响。【方法】64例急性冠脉综合征患者随机分为阿托伐他汀治疗组和常规治疗组，经过4周治疗，分别检测治疗前后血浆内脂素、C－反应蛋白（c—reactiveprotein，CRP）水平。另设30例健康受试者为对照组。【结果】与对照组相比，治疗前阿托伐他汀治疗组和常规治疗组的内脂素、CRP水平明显增高（P〈0．05），但两治疗组间差异无显著性（P〉0．05）；治疗4周后，阿托伐他汀治疗组的内脂素、CRP水平比对照组低（P〈0．05），而常规治疗组内脂素、CRP水平水平变化不明显（P〉0．05）。【结论】阿托伐他汀通过下调内脂素水平在急性冠脉综合征的发病机制中发挥抗炎作用。

[Objective]To investigate the effect of Atorvastatin on the levels of C-reactive protein（CRP） and visfatin in patients with acute coronary syndrome. [Methods]Sixty-four patients with acute coronary syndrome were randomly divided into Atorvastatin treatment group and conventional treatment group. Thirty health people were chosed to control group. After four weeks treatment, the plasma visfatin and CRP levels were examined and correlations were evaluated before and after treatment. [Results]Compared with control group, the levels of visfatin and CRP increased significantly in Atorvastatin treatment group and conventional treatment group（ P 〈0.05）, but no significantly difference between the two treatment groups（ P 〉0.05）. After four weeks treatment, the levels of visfatin and CRP significantly decreased in patients of Atorvastatin treatment group （ P 〈 0. 05）, but no significantly changes in conventional treatment group （ P 〉 0. 05）. [Conclusion]Atorvastatin can play Anti-inflammatory roles in the patients with acute coronary syndrome by declining the plasma visfatin level.